Evidence map›Paper›PMID 40597366›Full record

ArticleCancer cell international2025

An EcDNA gene-based risk model and functional verification of a key ec-lncRNA AC016394.2 for prostate cancer.

JiangPing Qiu, Jiang Wu, Nan Zhou, Cong Lai, Xin Huang, Cheng Liu, XiaoQing Yuan, Kewei Xu

Abstract read
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

JiangPing Qiu *Guangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, 516621, China.
Jiang Wu *Guangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, 516621, China.
Nan Zhou *Research Center, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, 510370, China.
Cong LaiDepartment of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yanjiang West Road, Guangzhou, Guangdong, 510000, China.
Xin HuangDepartment of Urology, Ganzhou People's Hospital, Ganzhou, Jiangxi, 341000, China.
Cheng LiuDepartment of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yanjiang West Road, Guangzhou, Guangdong, 510000, China. liuch278@mail.sysu.edu.cn.
XiaoQing YuanGuangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, 516621, China. yuanxq7@mail.sysu.edu.cn.
Kewei XuGuangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, 516621, China. xukewei@mail.sysu.edu.cn.

Funding

Ganzhou Municipal Directive Science and Technology Project GZ2024ZSF036Guangdong Basic and Applied Basic Research Foundation 2024A1515030038Guangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment 2024B1212030002Jiangxi Provincial Health Technology Project 202410850Key-Area Research and Development Program of Guangdong Province 2023B1111030006National Natural Science Foundation of China 82372766The Ganzhou Municipal"Science and Technology National Regional Medical Center" Joint Project 2023990044
6 · The paper itself

Abstract

backgroundProstate cancer(PCa) ranks among the most frequently diagnosed malignancies in men. The progression and heterogeneity of tumors pose significant challenges to clinical prognosis and treatment strategies. Recently, extrachromosomal DNA(ecDNA) has emerged as a critical player in cancer biology, influencing tumor progression, metastasis, and resistance to therapy. Oncogenes and regulatory sequences carried on ecDNA(ecDNA genes) can significantly alter the biological characteristics of tumors and their clinical outcomes.

methodsIn this study, we obtained ecDNA genes specifically expressed in PCa from the ECGA database. To construct a prognostic risk model for Biochemical Recurrence-Free Survival (BRFS), the two most common types of ecDNA genes which are protein-coding genes and long non-coding RNAs, were analyzed using Cox regression and LASSO regression techniques. Through KEGG/GO pathway enrichment analysis, we identified relevant pathways and analyzed the immune cell infiltration status. Functional assays, such as colony formation, CCK-8, migration, and invasion assays, were employed to assess the cellular functions of a key lncRNA AC016394.2.

resultsOur analysis identified six key ecDNA lncRNAs(ec-lncRNAs), including the ec-lncRNA AC016394.2, with significant prognostic value in PCa. By employing our risk scoring model, patients were classified into high-risk and low-risk groups, revealing significant differences in their BRFS outcomes. The model demonstrated strong predictive accuracy and clinical relevance. The 1/3/5-year AUC of the model is close to 0.8, which is higher than most common clinical indicators such as Gleason score and TM staging. KEGG and GO pathway enrichment analyses revealed that the high-risk group was predominantly enriched in immune-related pathways. Additionally, immune cell infiltration analysis demonstrated notable differences in the distribution of specific immune cell populations between the high-risk and low-risk groups. Knockdown of AC016394.2 inhibited PCa cell proliferation, migration, and invasion.

conclusionsThis study presents a novel ecDNA gene-based prognostic risk model for PCa, highlighting the functional importance of ec-lncRNA AC016394.2. These findings offer valuable insights into the biological role of ec-lncRNAs, highlighting their potential as targets for precision oncology and therapeutic intervention.

Indexed as

AC016394.2EcDNA genePrognostic modelProstate cancerTCGA

Identifiers

PMID40597366
PMCPMC12211912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.